ALPHAMAB ONCOLO.DL-000002 risk profile
50 Elevated one input has moved against it
Measured 1 September 2026 from 3NK's filed statements. Recomputed nightly.
50 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 75 | Stretched | Stable | Drawdown from the 52-week high — 43.5% |
| Operating pressure | 44 | Elevated | Worsening | Costs outgrowing revenue — +44.9 percentage points |
| Cash conversion | 100 | Acute | Worsening | Capital spending against operating cash — -0.26x |
| Leverage and coverage | 35 | Normal | Worsening | Interest cover — -5.61x |
| Competitive position | 39 | Normal | Stable | Operating-margin gap against peers — -20.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for ALPHAMAB ONCOLO.DL-000002